Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study

被引:100
作者
Orio, F
Palomba, S
Cascella, T
De Simone, B
Manguso, F
Savastano, S
Russo, T
Tolino, A
Zullo, F
Lombardi, G
Azziz, R
Colao, A
机构
[1] Univ Naples Federico II, Dept Mol Clin Endocrinol & Oncol, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Obstet & Gynecol, I-80131 Naples, Italy
[3] Univ Naples Federico II, Dept Clin & Expt Med, Gastroenterol Unit, I-80131 Naples, Italy
[4] Univ Naples Federico II, Inst Internal Med & Metab Dis, Gastroenterol Unit, I-80131 Naples, Italy
[5] Univ Catanzaro Magna Graecia, Dept Obstet & Gynecol, I-88100 Catanzaro, Italy
[6] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA
关键词
D O I
10.1210/jc.2005-0965
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Recent data indicate that women affected by the polycystic ovary syndrome ( PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients. Objective: The objective of this study was to evaluate the effects of 6 months of metformin administration on endothelial structure and function in women with PCOS. Design: This was a prospective, baseline- controlled, clinical study. Setting: The study was performed at University Federico II ( Naples, Italy). Patients: Thirty young normal- weight women with PCOS without additional metabolic or cardiovascular diseases were studied. Interventions: Metformin ( 850 mg daily) was administered for 6 months. Mean Outcome Measures: The main outcome measures were complete hormonal profile, including total testosterone, SHBG, dehydroepiandrosterone sulfate, prolactin, and gonadotropin levels; serum insulin and glucose levels during a 75- g 2- h oral glucose tolerance test; plasma endothelin- 1 concentrations ( picomoles per liter +/- SD); serum lipid profile; brachial artery baseline diameter ( millimeters +/- SD), diameter after reactive hyperemia ( millimeters +/- SD), and flow-mediated dilation ( percentage +/- SD); and the intima media thickness ( millimeters +/- SD) on both common carotid arteries. Results: After treatment, SHBG levels and the free androgen index changed significantly ( P < 0.001). High- density lipoproteins and the area under curve for glucose/ area under curve for insulin ratio also significantly ( P < 0.001) increased, whereas low- density lipoproteins and plasma endothelin- 1 levels were significantly ( P < 0.001) reduced. No other change was found in any of the biochemical parameters evaluated. A significant difference was observed in brachial artery baseline diameter ( 3.24 +/- 0.30 vs. 3.0 +/- 0.30), flow- mediated dilation ( 14.30 +/- 1.90 vs. 15.70 +/- 1.50) ( P < 0.01, each), diameter after reactive hyperemia ( 3.70 +/- 0.30 vs. 3.55 +/- 0.10) ( P < 0.05), and intima media thickness ( 0.53 +/- 0.09 vs. 0.40 +/- 0.07) ( P < 0.001) after metformin treatment in comparison with baseline values. Conclusions: A 6- month course of metformin improves endothelial structure and function in young, normal- weight women with PCOS.
引用
收藏
页码:6072 / 6076
页数:5
相关论文
共 37 条
[1]   Cardiovascular consequences of polycystic ovary syndrome [J].
Amowitz, LL ;
Sobel, BE .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (02) :439-+
[2]   Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome [J].
Apridonidze, T ;
Essah, PA ;
Iuorno, MJ ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :1929-1935
[3]   Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span [J].
Azziz, R ;
Marin, C ;
Hoq, L ;
Badamgarav, E ;
Song, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4650-4658
[4]   Endothelial dysfunction - A marker of atherosclerotic risk [J].
Bonetti, PO ;
Lerman, LO ;
Lerman, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :168-175
[5]   Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters [J].
Carmina, E ;
Chu, MC ;
Longo, RA ;
Rini, GB ;
Lobo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :2545-2549
[6]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[7]   Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome [J].
Cibula, D ;
Cífková, R ;
Fanta, M ;
Poledne, R ;
Zivny, J ;
Skibová, J .
HUMAN REPRODUCTION, 2000, 15 (04) :785-789
[8]  
De Jager J, 2005, J INTERN MED, V257, P100
[9]   Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy [J].
Diamanti-Kandarakis, E ;
Spina, G ;
Kouli, C ;
Migdalis, I .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :4666-4673
[10]   HYPERANDROGENIC ANOVULATION (PCOS) - A UNIQUE DISORDER OF INSULIN ACTION ASSOCIATED WITH AN INCREASED RISK OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DUNAIF, A .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 :S33-S39